Inara India Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 0.50 M
- Revenue Growth 32.81%
- Profit Growth 1347.60%
- Ebitda -110.86%
- Net Worth 24.20%
- Total Assets 11.63%
About Inara India Pharmaceuticals
Inara India Pharmaceuticals Private Limited (IIPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 March 2017 (Seven years and 11 months 0 days old ). Its registered office is in 24 Parganas, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Akash Poddar and Imtiyaz Alam serve as directors at the Company.
Company Details
-
Location
24 Parganas, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999WB2017PTC219889
-
Company No.
219889
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Mar 2017
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Inara India Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akash Poddar
|
Director | 10-Mar-2017 | Current |
|
Imtiyaz Alam
|
Director | 01-Feb-2023 | Current |
Financial Performance of Inara India Pharmaceuticals.
Inara India Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 32.81% increase. The company also saw a substantial improvement in profitability, with a 1347.6% increase in profit. The company's net worth Soared by an impressive increase of 24.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Inara India Pharmaceuticals?
In 2019, Inara India Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Idbi Bank Limited : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Oct 2019 | Idbi Bank Limited | ₹0.50 M | Open |
How Many Employees Work at Inara India Pharmaceuticals?
Unlock and access historical data on people associated with Inara India Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Inara India Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inara India Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
